Aluminium (Al) levels evaluated in the urine samples of examinated subjects, following chelation test (dark) and after ten chelation therapies with EDTA (light), expressed as mean ± SEM of μg/g creatinine. The studied subjects were healthy patients, patients affected by multiple sclerosis (MS), and patients affected by all neurodegenerative diseases (ND). The levels of Al in both MS and ND patients were significantly higher with respect to those obtained in healthy subjects following chelation test ( versus healthy). After chelation therapies with EDTA, the levels of Al were significantly lower than that obtained following chelation test (# versus and ## versus ).
